Wave Life Sciences Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WVE research report →
Range $10 – $14
Price Chart
About the company
Wave Life Sciences Ltd. , a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
- CEO
- Paul Bolno
- IPO
- 2015
- Employees
- 317
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on WVE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $504.91M
- P/E
- -2.54
- PEG
- 0.04
- P/S
- 7.56
- P/B
- 1.38
- EV/EBITDA
- -1.86
- Div Yield
- 0.00%
- Gross Margin
- 96.81%
- Op Margin
- -320.94%
- Net Margin
- -296.86%
- ROE
- -44.48%
- ROIC
- -49.75%
Latest fiscal year · YoY change
- Revenue
- $42.73M-60.5%
- Gross Profit
- $33.88M-68.7%
- Op Income
- $-215,383,000
- Net Income
- $-204,378,000-110.7%
- EPS
- $-1.21-72.9%
- OCF Growth
- -24.1%
- FCF Growth
- -23.9%
- 52W High
- $21.73
- 52W Low
- $2.54
- 50D MA
- $3.57
- 200D MA
- $6.71
- Beta
- -1.44
- RSI (14)
- 29
- Avg Volume
- 3.12M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Wave Life Sciences said it is advancing WVE-007 and WVE-006 on track, with Q3 revenue of $13.2 million and cash runway into the third quarter of 2028.· October 27, 2026
- Q3 revenue was $13.2 million, up from $7.6 million a year ago, driven by the GSK collaboration.
- R&D rose to $53.8 million and G&A to $25.4 million as Wave pushed WVE-007 and RNA-editing programs forward.
- Wave ended Q3 with $431 million in cash, cash equivalents and marketable securities, and expects an additional $12 million GSK milestone in Q4.
- Management said FDA discussions support a single registrational trial design for WVE-006 with a one-year interim readout for potential accelerated approval and a two-year path to full approval.
- For WVE-007, Wave said phase II-A obesity trials are underway, with 600 mg phase I data expected this quarter and a maintenance study slated for Q4 initiation.
Revenue for the third quarter of 2026 was $13.2 million, versus $7.6 million in the prior-year quarter, tied to the GSK collaboration. Research and development expense was $53.8 million, versus $45.9 million a year ago; G&A was $25.4 million, versus $18.1 million; and net loss was $61.9 million, versus $53.9 million. The company ended the quarter with $431 million in cash, cash equivalents and marketable securities, which it expects is enough to fund operations into the third quarter of 2028. Wave also expects a $12 million GSK milestone in the fourth quarter. Management reiterated that WVE-007 600 mg data are expected this quarter, the post-incretin maintenance trial is on track for Q4, WVE-006 data from the 600 mg monthly cohort are expected in Q4, and WVE-008 remains on track for a CTA submission in 2026.
Paul Bolno framed Wave as a platform company applying proprietary chemistry across siRNA and RNA editing, with particular emphasis on durability, selectivity, and translational data. He repeatedly positioned WVE-007 as a differentiated obesity approach that could preserve muscle while reducing fat, potentially complementing incretins and even serving in maintenance after GLP-1 cessation. On WVE-006, he emphasized the strategic significance of the FDA feedback, saying Wave sees an efficient path to both accelerated and full approval with a single trial design.
Kyle Moran highlighted the quarter’s financials: $13.2 million in revenue, $53.8 million in R&D, $25.4 million in G&A, and a $61.9 million net loss. He said the higher expenses reflected continued investment in clinical programs, including the phase II portion of INLIGHT and progress across the RNA-editing pipeline. He also noted $431 million in cash, cash equivalents and marketable securities, with runway into Q3 2028, and called out an expected $12 million milestone from GSK in Q4, while excluding future collaboration payments from that runway estimate.
Analysts focused on WVE-006’s FDA path, asking about trial size, the basis for accelerated versus full approval, and whether the agency is effectively distinguishing RNA editing from DNA editing. Management said the plan is a single two-year registrational study with a one-year interim analysis for accelerated approval, and that they would not disclose exact biomarker thresholds competitively; they also said the FDA was supportive of the LC-MS assay and of the MZ-like phenotype concept. Questions also centered on WVE-007’s 5% weight-loss bar, body-composition endpoints, dose selection for maintenance versus induction, and whether 600 mg would change the regimen; management said the company is still analyzing whether to present three-month or six-month data and that lower doses already show durable knockdown. On enrollment, management said AATD registrational recruitment should benefit from large patient registries and that the global study is not limited by the same hepatic constraints seen in some competitor programs.
The bull case from the call is that Wave believes it has multiple differentiated shots on goal, with WVE-007 showing fat-loss biology that management says may preserve muscle and work as an add-on or maintenance therapy to incretins. FDA feedback on WVE-006 appears constructive, and the company now plans for a single registrational trial that could support both accelerated and full approval. Cash runway into 2028 and a pending GSK milestone reduce near-term financing pressure.
The main risks raised on the call are clinical and regulatory execution: WVE-007 still needs to prove the phase II-A obesity data can translate into the 5% weight-loss bar, and management has not yet locked timing for the first data cut. WVE-006 still depends on additional dose, duration, and endpoint work before the registrational strategy is finalized, and management declined to disclose the exact full-approval biomarker package. The company is also spending more to advance the pipeline, with R&D and G&A both up year over year, and several key readouts are still ahead rather than in hand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.8%
- Shares Outstanding
- 197.23M
- Float Shares
- 165.32M
of shares held by institutions
250 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 26.98M | 0 |
| Blackrock, Inc. | 21.09M | ▲ 1.89M |
| Gsk PLC | 18.25M | 0 |
| Maverick Capital Ltd | 9.72M | ▼ 557.55K |
| Two Sigma Investments, LP | 5.90M | ▲ 2.19M |
| State Street Corp | 5.66M | ▲ 819.72K |
| Readystate Asset Management LP | 5.54M | ▲ 810.73K |
| 683 Capital Management, LLC | 5.46M | ▲ 510.00K |
| Primecap Management Co | 5.13M | ▼ 229.59K |
| M28 Capital Management LP | 4.59M | 0 |
| Fmr LLC | 3.84M | ▼ 1.09M |
| Qube Research & Technologies Ltd | 3.68M | ▲ 899.36K |
Held by 243 ETFs
Biggest fund positions in WVE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 5, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 64,000 |
| Oct 5, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 10,700 |
| Oct 5, 26 | Verdine Gregory L. | other | 10,700 |
| Oct 5, 26 | Verdine Gregory L. | other | 64,000 |
| Oct 5, 26 | Tan Aik Na | other | 64,000 |
| Oct 5, 26 | Tan Aik Na | other | 10,700 |
| Oct 5, 26 | TAKANASHI KEN | other | 64,000 |
| Oct 5, 26 | TAKANASHI KEN | other | 10,700 |
| Oct 5, 26 | CORRIGAN MARK | other | 64,000 |
| Oct 5, 26 | CORRIGAN MARK | other | 10,700 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our WVE coverage
Recent articles, reports, and earnings notes.
No research on WVE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WVE report →Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
globenewswire.com · Nov 13
Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London
globenewswire.com · Nov 11
Wave Life Sciences: Reversing Stock Losses Tricky Despite Near-Term AATD Readout
seekingalpha.com · Nov 10
Wave: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 8
Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript
seekingalpha.com · Nov 4
WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program
marketbeat.com · Nov 4
Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 27
WAVE Life Sciences Q3 Earnings Call Highlights
marketbeat.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.